Dapagliflozin 5mg

DRUG5 trials

Conditions

Acute Kidney InjuryDiabetes Mellitus, Type 1Left Cardiac CatheterizationPercutaneous Coronary InterventionRefractory AscitesSodium-glucose Co-transporter 2 InhibitorsType 1 Diabetes MellitusType1 Diabetes Mellitus

Early Phase 1

Dapagliflozin to Prevent the Incidence of Contrast Induced Nephropathy After Heart Catheterization and Percutaneous Coronary Intervention

NCT04806633

G.Gennimatas General HospitalAcute Kidney Injury, Left Cardiac Catheterization, Percutaneous Coronary Intervention +1

Start: 2021-04-01End: 2023-12-01Target: 1722Updated: 2021-03-19

Phase 1

The PK and PD of Dapagliflozin Therapy in Combination With Insulin in Japanese Subjects With T1DM

CompletedNCT02582840

AstraZenecaType 1 Diabetes Mellitus

Start: 2015-10-31End: 2016-06-30Updated: 2019-01-18

Dapagliflozin Effects on Hypoglycemia

CompletedNCT03704818

University of California, San DiegoType1 Diabetes Mellitus

Start: 2018-10-08End: 2021-11-30Updated: 2024-01-23

Phase 2

Clinical Study to Evaluate the Efficacy and Safety of Dapagliflozin in Patients With Refractory Cirrhotic Ascites

Not yet recruitingNCT06919523

Mansoura UniversityRefractory Ascites

Start: 2025-04-15End: 2025-09-15Target: 70Updated: 2025-04-09

Phase 3

Adolescent Type 1 Diabetes Treatment With SGLT2i for hyperglycEMia & hyPerfilTration Trial

NCT04333823

The Hospital for Sick ChildrenDiabetes Mellitus, Type 1

Start: 2020-12-11End: 2024-05-31Target: 100Updated: 2023-11-21

Related Papers

SGLT2 inhibition modulates metabolic, vascular, and inflammatory molecular markers in the kidney in youth with type 1 diabetes.

2026-07-22

Adjunct-to-insulin therapy using SGLT2 inhibitors in youth with type 1 diabetes: a randomized controlled trial.

2025-06-063 citations

Pharmacokinetics (PK) and Pharmacodynamics (PD) of Dapagliflozin (DAPA) in Combination with Insulin in Japanese Patients with T1D

Diabetes2018-06-22